1. The compounds described in this specification are sodium channel inhibitors for the treatment of various diseases, including cardiovascular diseases and diabetes. 1. Claim 1: a formula compound (1),Cy was arilo, cycloquilo, heatcycle, cycloquine, cycloquine, O heterosexual； Q was covalent-o-quileno c8332083331；-Nr.1 - lessor c8320331；Lease No. c832221. Alquenileno c832220 or c83222 asphalt；M is 0, 1, 2 or 3； n is 0, 1, 2, 3, 4 or 5； each r183044 is selected independently from the halo group, - no.8322；-CN-SF832525，-Yes (ch832323) 8323；-O-R830404，-S-R830404，-C (O) -R-C (O) -OR-N (R) (R)-C (O) -N (R) (R)-N (R) -C (O) -R-N (R) -C (O) -OR-N (R) -S (O) -R-S (O) -R-O-S (O) -R-S (O) -N (R) (R)1. Lease land No. c833218331 and 832626；Alquenilo C83228331832424；1. C 83228331 asphalt；1. Cyclopentyl propyl, arillo, isopropyl and isopropyl, among which asphalt c83321316262；Alquenilo C83228331832424；1. C 83228331 asphalt；1. One, two or three substitutes independent of halogen-n ° 832222 can be selected to replace cyclopropyl, cyclopropyl, isopropyl or non cyclopropyl；Arilo, heterosexual, heterosexual, acquilo c832131；Halogenated tar c83218323；Bicycle, n (830404) (R2),-C (O) -R-C (O) -OR-C (O) -N (R) (R)-CN-Y-O-R830404；R2 es asphalt c8321131； 832626-r83099；-L-R83099；-L-tar compound c8321c833183226-r83099；-C83218c833126-l-r83099 or c83218831832626-l-acquileno c83331-r832609；I am what I am.- yes.-C (O) --NHS (O) --S（O）8322NH---C (O) NH- o -NHC (O) -2. When RZ is - l-r83090, o-l-tar layer c832183316263-r83099；So he's not - O- yes.-NHS (O) - o -NHC (O) -Each cubic meter is an independent hydrogen, deuterium, tar c833218331832626；1. C833218331832626 tar can be selectively replaced by one, two or three substitutes independent of halogen group；1. Cyclopentanediol, arilo, isopropene, isopropene, isopropene, n (km2)；-C (O) -R-C (O) -OR-C (O) -N (R) (R)-CN-Y-O-R830404；1. Among the non halogenated-0.8322 substitutes, 1, 2 or 3 non halogenated-1, 2 or 3 substitutes can be selected to replac
